Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial

• Published in: Integrative cancer therapies Vol. 21; p. 15347354221086663
• Main Authors: Li, Chia-Ling, Hsia, Te-Chun, Yang, Su-Tso, Chao, Kun-San Clifford, Tu, Chih-Yen, Chen, Hung-Jen, Li, Chia-Hsiang
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.01.2022; SAGE PUBLICATIONS, INC
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - drug therapy; Afatinib - adverse effects; c-Met protein; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Chinese medicine; Epidermal growth factor; Epidermal growth factor receptors; ErbB Receptors - genetics; Fatigue, Treatment Side Effects and Rehabilitation; Humans; Lung cancer; Lung Neoplasms - genetics; Lungs; Medicine, Chinese Traditional - methods; Metastases; Mutation; Pilot Projects; Placebos; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Quality of life; Skin; Survival; Toxicity; Traditional Chinese medicine; advanced lung adenocarcinoma; traditional Chinese medicine; EGFR-TKI; quality of life; prophylaxis; skin toxicity
• ISSN: 1534-7354; 1552-695X
• DOI: 10.1177/15347354221086663

Objectives: To evaluate the efficacy of prophylactic traditional Chinese medicine (TCM) on skin toxicities in patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a randomized-controlled trial (RCT). Materials and methods: This pilot study was a prospective, single-center, double-blinded RCT. The study enrolled patients with a new diagnosis of locally advanced and metastatic lung adenocarcinoma harboring EGFR mutations who were treated with first-line afatinib from July 1, 2016 to December 31, 2017. Thirty patients who met the inclusion and exclusion criteria were assigned to the TCM and placebo groups with simple randomization. TCM and placebo were initiated at the same time as afatinib and were administered for 3 months. The survival of each subject was followed until 3 years. Results: There were 36 patients with newly diagnosed lung adenocarcinoma during the study period. After the exclusion of 6 patients, the remaining 30 patients were assigned to the TCM (n = 14) and placebo (n = 16) groups comprising the intention-to-treat population. The time to first skin toxicity was 22.3 days in the TCM group and 17.6 days in the placebo group (P = .510) in the per-protocol population. The analysis of the present pilot study results determined that the difference in time to first skin toxicity between the 2 groups would reach statistical significance with a sample size of 237 based on a power of 0.8. There were significant differences in certain subscales of quality of life between the TCM and placebo groups; however, there was no significant difference in progression-free survival or overall survival between the 2 groups. Conclusions: Integrative TCM may prolong the time to first skin toxicity in patients with advanced lung adenocarcinoma treated with first-line afatinib. Prophylactic TCM could delay skin toxicity of any grade and reduce the incidence of grade 3 skin toxicity. Future large-scale RCTs are warranted to validate these findings. Trial Registration: ClinicalTrials.gov, NCT05204758. Registered on 24 Jan 2022.